WEATHER ALERT: January 25, 2026 (5:15 PM): We are actively monitoring the weather in our area to ensure patient and staff safety. Our offices will be CLOSED on Monday (January 26) with an ON-TIME OPENING on Tuesday (January 27). Patients in active cancer treatment will continue to be prioritized to ensure continuity of care. If you are undergoing active cancer treatment, a team member will reach out to advise of any changes to your appointment. Please continue to check our website for the latest weather updates. Thank you for your patience and understanding.
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
